Trials / Unknown
UnknownNCT04500379
Reliability and Validity of FIBSER, STAR-P, HEA Scale The Reliability and Validity of Chinese Version of FIBSER, STAR-P, HEA Scale in Depression Assessment
The Reliability and Validity of Chinese Version of FIBSER, STAR-P, HEA Scale in Depression
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- Shanghai Mental Health Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
According to the survey of the World Health Organization, the number of patients with depression in the world has reached 350 million, has becoming the primary cause of disability and the main disease burden worldwide. In order to better dealing with adverse reactions, improving the doctor-patient relationship and optimizing the treatment cost, FIBSER, STAR-P and HEA Health Economics Follow-up Evaluation Scale are selected as simple and quick evaluation scales to evaluate the influence, doctor-patient relationship and social and economic benefits after drug treatment in clinical treatment. At present, the reliability and validity of FIBSER, STAR-P and HEA scales will be verified the reliability and validity of the above three scales in depressive disorder, aiming at enriching the treatment of depressive patients based on assessment, thus improving the compliance of medication for depressive disorder, improving the doctor-patient relationship and reducing the total burden of social diseases.
Detailed description
In this study, the reliability and validity of FIBSER Scale, Doctor-patient Relationship Scale-Patient Edition (STAR-P) and HEA in Chinese population will be verified to increase the diversity and selectivity of domestic assessment tools. This study includes two steps. 1. baseline: demographic data, HAM-D, HAM-A, YMRS, drug side effects scale:FIBSER, TESS; doctor-patient relationship scale :STAR-P, PDRQ-15;Health economics follow-up evaluation scale :SDS and HEA were evaluated. 2. follow-up (4 weeks): HAM-D, HAM-A, YMRS, FIBSER, STAR-P and HEA scale in order to verify the reliability of retest.
Conditions
Timeline
- Start date
- 2020-07-24
- Primary completion
- 2021-10-05
- Completion
- 2022-12-28
- First posted
- 2020-08-05
- Last updated
- 2022-09-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04500379. Inclusion in this directory is not an endorsement.